UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Repare Therapeutics Inc (RPTX)

Repare Therapeutics Inc (RPTX)
0.9011 x 1 0.9675 x 2
Pre-market by (Cboe BZX)
0.9000 unch (unch) 04/11/25 [NASDAQ]
0.9011 x 1 0.9675 x 2
Pre-market 0.9500 +0.0500 (+5.56%) 05:36 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.8972
Day High
0.9490
Open 0.9490
Previous Close 0.9000 0.9000
Volume 385,700 385,700
Avg Vol 251,360 251,360
Stochastic %K 7.64% 7.64%
Weighted Alpha -68.89 -68.89
5-Day Change -0.0999 (-9.99%) -0.0999 (-9.99%)
52-Week Range 0.8900 - 4.2900 0.8900 - 4.2900
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,260
  • Shares Outstanding, K 42,511
  • Annual Sales, $ 53,480 K
  • Annual Income, $ -84,690 K
  • EBIT $ -94 M
  • EBITDA $ -97 M
  • 60-Month Beta 0.91
  • Price/Sales 0.72
  • Price/Cash Flow N/A
  • Price/Book 0.25
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.00
  • Most Recent Earnings $-0.67 on 03/03/25
  • Next Earnings Date 05/06/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 380.99% ( +74.50%)
  • Historical Volatility 44.65%
  • IV Percentile 90%
  • IV Rank 56.43%
  • IV High 665.95% on 02/12/25
  • IV Low 12.00% on 08/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 65
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 789
  • Open Int (30-Day) 803

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.65
  • Number of Estimates 1
  • High Estimate -0.65
  • Low Estimate -0.65
  • Prior Year 0.30
  • Growth Rate Est. (year over year) -316.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8900 +1.12%
on 04/10/25
Period Open: 1.1500
1.1900 -24.37%
on 03/12/25
-0.2500 (-21.74%)
since 03/11/25
3-Month
0.8900 +1.12%
on 04/10/25
Period Open: 1.3800
1.4400 -37.50%
on 01/13/25
-0.4800 (-34.78%)
since 01/10/25
52-Week
0.8900 +1.12%
on 04/10/25
Period Open: 3.9000
4.2900 -79.02%
on 07/19/24
-3.0000 (-76.92%)
since 04/11/24

Most Recent Stories

More News
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

/CNW/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies...

ONCY : 0.6229 (+24.56%)
RPTX : 0.9000 (unch)
IMRX : 1.2900 (+4.03%)
ONC.TO : 0.88 (+25.71%)
RNXT : 0.7720 (-2.40%)
CRGX : 4.26 (+4.67%)
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite significant advances in oncology research, challenges remain as the American Cancer Society...

ONCY : 0.6229 (+24.56%)
PYXS : 0.9587 (+5.67%)
RPTX : 0.9000 (unch)
IMRX : 1.2900 (+4.03%)
CVM : 0.3060 (+45.09%)
ONC.TO : 0.88 (+25.71%)
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund

/CNW/ - Alberta Enterprise Corporation (AEC) announced today that it has invested US$7.5 million into Amplitude Ventures' US$192-million Fund II to give early...

RPTX : 0.9000 (unch)
Amplitude Ventures Closes $263 Million Precision Medicine Venture Fund

/CNW/ - Amplitude Ventures, a full-stack venture capital firm focused on investing in precision medicine at the intersection of biology and AI, today announced...

RPTX : 0.9000 (unch)
Wall Street Thinks This Cathie Wood Stock Could Jump by 187%

This small-cap biotech stock holds enormous growth potential.

TSLA : 252.31 (-0.04%)
ROKU : 60.22 (+1.60%)
SHOP : 83.71 (-1.09%)
RPTX : 0.9000 (unch)
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board...

RPTX : 0.9000 (unch)
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented initial data from its ongoing Phase 1/2 TRESR clinical...

RPTX : 0.9000 (unch)
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib...

RPTX : 0.9000 (unch)
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended...

RPTX : 0.9000 (unch)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repare Therapeutics Inc. - RPTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such...

RPTX : 0.9000 (unch)

Business Summary

Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare...

See More

Key Turning Points

3rd Resistance Point 0.9854
2nd Resistance Point 0.9672
1st Resistance Point 0.9336
Last Price 0.9000
1st Support Level 0.8818
2nd Support Level 0.8636
3rd Support Level 0.8300

See More

52-Week High 4.2900
Fibonacci 61.8% 2.9912
Fibonacci 50% 2.5900
Fibonacci 38.2% 2.1888
Last Price 0.9000
52-Week Low 0.8900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar